Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 220

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 220
---
 |

|                                               |     | Successor         
 Unaudited         |           |   |     |          |     |     |                  |     |     |                           |   |
|                                               |     | Number of options |           |   |     | Weighted 
 average  
 exercise 
 price    |     |     | Weighted         
 average          
 remaining        
 contractual      
 terms (in years) |     |     | Aggregate intrinsic value |   |
| Outstanding at January 1, 2025                |     |                   | 4,960,000 |   |     |          | 0.3 |     |                  | 6.1 |     |                           | - |
| Forfeited                                     |     |                   |  (690,000 | ) |     |          |   - |     |                  |   - |     |                           | - |
| Outstanding at March 31, 2024                 |     |                   | 4,270,000 |   |     |          | 0.3 |     |                  | 5.8 |     |                           | - |
| Vested and expected to vest at March 31, 2025 |     |                   | 4,270,000 |   |     |          | 0.3 |     |                  | 5.3 |     |                           | - |
| Exercisable at March 31, 2025                 |     |                   | 3,347,500 |   |     |          | 0.3 |     |                  | 4.9 |     |                           | - |

<div align='center'>F-42</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

NOTE 6 – SUBSEQUENT EVENT

On April 1, 2025, the Board of Directors approved
a grant to Company’s Chairman of 240,000 stock options at an exercise price of $0.30 per share. The options are scheduled to vest
on a quarterly basis over two years in equal quarterly instalments of 30,000 options, beginning with the quarter ended March 31, 2025.
The options are exercisable within eight years from grant date.

On April 8, 2025, Company’s subsidiary Lipovation,
by a resolution of its Board of Directors has terminated it’s share option plan and received from all option grantees waivers